These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30078657)

  • 41. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
    Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
    PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.
    Plosker GL
    Drugs R D; 2012 Dec; 12(4):239-44. PubMed ID: 23017130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
    Sun SL; Gao YQ; Yin J; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
    Yamin D; Atkins KE; Remy V; Galvani AP
    Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of five years of rotavirus vaccination in Finland - And the associated cost savings in secondary healthcare.
    Leino T; Baum U; Scott P; Ollgren J; Salo H
    Vaccine; 2017 Oct; 35(42):5611-5617. PubMed ID: 28893475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
    Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
    J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
    Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan.
    Freiesleben de Blasio B; Flem E; Latipov R; Kuatbaeva A; Kristiansen IS
    Emerg Infect Dis; 2014 Jan; 20(1):29-37. PubMed ID: 24378188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.
    Dhont P; Trichard M; Largeron N; Rafia R; Bénard S
    J Med Econ; 2008; 11(3):431-48. PubMed ID: 19450097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of 2 rotavirus vaccines against rotavirus disease in Taiwanese infants.
    Chang WC; Yen C; Wu FT; Huang YC; Lin JS; Huang FC; Yu HT; Chi CL; Lin HY; Tate JE; Parashar UD; Wu HS; Hsiung CA
    Pediatr Infect Dis J; 2014 Mar; 33(3):e81-6. PubMed ID: 24569388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost-effectiveness of rotavirus vaccination in Armenia.
    Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
    Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.